PharmaVentures advised Dogu Tip on its sale to Gulf Capital

OXFORD, UK, April 11th, 2013

PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive shares to the management.

PharmaVentures, a leading life science and healthcare advisory firm, was advisor to Doğu Tip and its shareholders.
Techno Group is the leading provider of diagnostic imaging services in the MENA region.  Gulf Capital is a leading MENA private equity firm based in Abu Dhabi with close to $2 billion in assets under management.

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva's Hlovovec Production Facility to Wood Pharma Holding

OXFORD, UK, December 19th, 2012

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi's divestment of its Zentiva subsidiary's production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

Stephen Waterman joins PharmaVentures

Oxford, UK, October 18th, 2012

PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare and investment communities.

PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund

Oxford, UK, March 21st, 2012

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index’s largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Protecting Cash Flow Through Licensing Terms is Critical for Biotech Success

Oxford, UK, March 19th, 2012

The pharmaceutical and biotechnology industry is undergoing considerable change as the patent cliff looms, fostering invention and change, and a strong need for successful partnering. There are also new opportunities to develop in emerging and emerged new markets. What impact are these changes having on companies as they seek partners, to strike the best deal? How can companies be sure that the deal terms they achieve, and associated royalties, are the best possible? The terms of licensing deals are turning back in favour of cash-rich pharmaceutical companies, and there are key lessons to be learned by any aspiring dealmaker.

Deal-making declines by 18% in a year as pharmaceutical companies tighten their belt

Oxford, UK,  January 25th,  2012

Overall pharmaceutical deal-making activity fell by 18% in 2011 as pharmaceutical companies cut R&D expenditure and streamlined their research and development activities, according to research conducted by the UK advisory firm PharmaVentures.

PharmaVentures’ client Sanofi wins Scrip ‘Outsourcing Deal of the Year Award’

Oxford, UK 12 January 2012 - PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi – Covance deal which won Scrip’s ‘Outsourcing Deal of the Year 2011’.

Pfizer, Sanofi and Genentech feature prominently in the Oncology edition of PharmaDeals’ new publication series; Essential Deal Trends

Oxford, UK, October 20th, 2011 - PharmaVentures today announced the launch of PharmaDeals® Essential Deal Trends: Oncology 2011. This new series of reports is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.

Pfizer Overtakes GSK but Trails Roche in PharmaDeals’ Corp-METRx Analysis of Deal Activity

Oxford, UK 26 September 2011 - PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.

PharmaVentures engaged by Astex Pharmaceuticals to Assist in the divestment of US facility

Oxford, UK 09 September 2011 - PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.


Watch our new promotional video



PharmaVentures InSights